#USA #Karyopharm #XPOVIO #Newton #Selinexor

Karyopharm's Q1 2026 Financial Report and Trial Updates

Karyopharm Therapeutics Inc., a leader in innovative cancer treatments, celebrated recent achievements in their latest financial report for the first quarter of 2026. These updates put the spotlight on important clinical milestones and the progress of their flagship drug, XPOVIO (selinexor).

Completion of Phase 3 Trial Enrollment

A significant highlight from the report is the successful completion of enrollment for the Phase 3 XPORT-EC-042 trial, targeting patients with advanced or recurrent endometrial cancer who possess TP53 wild-type tumors. Approximately 257 patients have joined this study, which aims to evaluate the efficacy of selinexor as a maintenance therapy following systemic treatment. Initial results from this trial are anticipated in mid-2026, which is a crucial timeline for Karyopharm as the company strives to enhance patient outcomes in this challenging cancer type.

Furthermore, data from the Phase 3 SENTRY trial focusing on myelofibrosis has been selected for a late-breaking presentation at the upcoming American Society of Clinical Oncology (ASCO) meeting on June 2. This timely presentation highlights Karyopharm’s dedication to showcasing their advancements in critical cancer therapies.

Financial Performance in Q1 2026

Karyopharm reported a total revenue of $35.1 million for the first quarter of 2026, marking an increase from $30 million in the same period last year. The net product revenue from XPOVIO alone stood at $29.2 million, representing a notable jump from $21.1 million in Q1 2025. Despite a decrease in demand attributed to competitive entry into the market, Karyopharm has successfully maintained its revenue stream, especially in the community healthcare setting, which constitutes approximately 60% of their net product revenues.

The company also saw a small rise in royalty revenues, totaling $1.9 million, as international partnerships expand due to the global approval of selinexor in over 50 countries. This expanded access emphasizes Karyopharm's commitment to broadening patient access to their innovative therapies worldwide.

Outlook for 2026 and Expectations

Looking forward, Karyopharm's management has reaffirmed its full-year revenue guidance, expecting total revenue to range between $130 million and $150 million, with U.S. XPOVIO net product revenue projected at $115 million to $130 million. This optimistic outlook reflects Karyopharm's strategic initiatives to increase market presence and enhance their product portfolio amid an evolving industry landscape.

Additionally, Karyopharm anticipates announcing topline results from the Phase 3 XPORT-EC-042 trial in mid-2026, a milestone that could significantly impact the therapeutic landscape for endometrial cancer treatments. They also aim to maintain the competitive edge of XPOVIO within multiple myeloma therapies while exploring new partnerships to facilitate the global launch of developed products.

Conclusion

In summary, Karyopharm Therapeutics remains at the forefront of cancer treatment innovation, demonstrated through its financial performance and progress in clinical trial enrollments. The promising developments in their ongoing studies coupled with solid revenue growth provide a robust foundation for the company as it navigates the complexities of the pharmaceutical landscape. Stakeholders and patients alike can look forward to what the remainder of 2026 holds for Karyopharm’s initiatives and the continued impact of XPOVIO as a leading treatment option in oncology.